Issue 24, 2013

Design of a platinum–acridine–endoxifen conjugate targeted at hormone-dependent breast cancer

Abstract

The synthesis of a novel pharmacophore comprising a DNA-targeted platinum–acridine hybrid agent and estrogen receptor-targeted 4-hydroxy-N-desmethyltamoxifen (endoxifen) using carbamate coupling chemistry and its evaluation in breast cancer cell lines are described.

Graphical abstract: Design of a platinum–acridine–endoxifen conjugate targeted at hormone-dependent breast cancer

Supplementary files

Article information

Article type
Communication
Submitted
14 dec 2012
Accepted
06 feb 2013
First published
07 feb 2013

Chem. Commun., 2013,49, 2415-2417

Design of a platinum–acridine–endoxifen conjugate targeted at hormone-dependent breast cancer

S. Ding, X. Qiao, G. L. Kucera and U. Bierbach, Chem. Commun., 2013, 49, 2415 DOI: 10.1039/C3CC38957J

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements